Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...